First Cohort Completed and Second Cohort of Ph 1/2 Study of INKmune™ NK Cell Therapy in Patients with Metastatic CRPC Initiated May 1, 2024
CHMP Adopts Positive Opinion Recommending Approval of Opdivo in Combination with Cisplatin and Gemcitabine for the 1L Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma May 1, 2024
XTANDI (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting May 1, 2024
Arvinas and Novartis to Develop and Commercialize PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer April 16, 2024
Three-Year Follow-up Data in BCG-Unresponsive NMIBC Show Durable Response to Treatment with ADSTILADRIN (nadofaragene firadenovec-vncg) in 2 Patient Cohorts April 16, 2024
Alliance A032103 (MODERN) Randomized, Ph 2/3 Adjuvant Trial in Urothelial Cancer announced April 9, 2024
Positive Surveillance Analysis from the Randomized Ph 3 IMvigor011 Trial in MIBC announced April 8, 2024
Pluvicto® pre-taxane label expansion filing planned in H2 2024 based on latest data from Ph 3 PSMAfore study April 8, 2024
China’s NMPA Accepts Supplemental BLA for enfortumab vedotin with KEYTRUDA for 1L Bladder Cancer April 2, 2024
Positive CHMP Opinion Received for XTANDI in Additional Recurrent Early Prostate Cancer Treatment Setting March 26, 2024
Rolling NDA submitted to the FDA for UGN-102; 12-month duration of response data from ENVISION expected to support completion of NDA submission March 19, 2024
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies March 12, 2024
U.S. FDA Approves Opdivo + Cisplatin + Gemcitabine for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma March 12, 2024
Vudalimab monotherapy generally well tolerated with encouraging clinical benefit for heavily-pretreated patients with high-risk metastatic CRPC March 5, 2024
Encouraging Safety & Efficacy Data in Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in metastatic CRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors Announced March 5, 2024
KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With RCC at an Increased Risk of Recurrence Following Nephrectomy February 26, 2024
KEYTRUDA Significantly Improved DFS as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized MIBC After Surgery February 26, 2024
SC Nivolumab Shows Noninferiority Compared to IV Opdivo (nivolumab) in Advanced or Metastatic ccRCC in CheckMate -67T Trial February 26, 2024
EMA Validates Type II Variation Application for PADCEV (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for 1L Treatment of Advanced Bladder Cancer February 26, 2024
PADCEV™ (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) Granted Priority Review by Japan’s MHLW for 1L Treatment of Advanced Bladder Cancer February 26, 2024
LAVA Therapeutics Announces Collaboration with Merck to Evaluate LAVA-1207 in Combination with KEYTRUDA January 31, 2024
Opdivo + CABOMETYX Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in 1L Advanced RCC January 31, 2024
